1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

NIVI - A $260m Vaccine R&D Initiative That Benefits From Wegovy Windfall

 
• By Kevin Grogan

The Novo Nordisk Foundation is funding a project to develop vaccines that generate a local immune response at the site of infection – in the case of respiratory diseases in the airways – which could help prevent even mild infections, block transmission and generate long-term immunity.

Mads Thomsen
Mads Krogsgaard Thomsen • Source: Novo Nordisk Foundation

The pile of cash building up from the success of Novo Nordisk A/S's weight loss drug Wegovy has spurred on the foundation that controls the Danish drugmaker to give the green light to a major new vaccines project that will aim to fight deadly airborne infections.

The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) is being backed to the tune of up to DKK1.8bn ($260m) with the goal of creating new or improved vaccines for respiratory diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.